Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | TCF4 | P15884 | 2/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1403300 | 0.98 | ALDH1A1 (0.64) | ALDH1A1RAB9APOLBNPC1LOXL2 | |
| SCHEMBL7263642 | 0.93 | POLB (0.69) | ALDH1A1RAB9APOLBNPC1LOXL2 | |
| SCHEMBL14380453 | 0.84 | ALDH1A1 (0.47) | ALDH1A1RAB9APOLBNPC1LOXL2 | |
| SCHEMBL28222851 | 0.84 | ALDH1A1 (0.47) | ALDH1A1RAB9APOLBNPC1LOXL2 | |
| SCHEMBL20984597 | 0.84 | ALDH1A1 (0.47) | ALDH1A1RAB9APOLBNPC1LOXL2 | |
| SCHEMBL1000086 | 0.84 | ALDH1A1 (0.47) | ALDH1A1RAB9APOLBNPC1LOXL2 | |
| SCHEMBL30444499 | 0.83 | RAB9A (0.66) | ALDH1A1RAB9APOLBNPC1LOXL2 | |
| SCHEMBL13808968 | 0.83 | RAB9A (0.65) | ALDH1A1RAB9APOLBNPC1LOXL2 | |
| SCHEMBL19647678 | 0.83 | RAB9A (0.65) | ALDH1A1RAB9APOLBNPC1LOXL2 | |
| SCHEMBL694145 | 0.83 | RAB9A (0.66) | ALDH1A1RAB9APOLBNPC1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528884-A | 1, 5-Diaryl-1, 2, 4-triazole derivative targeted at Myoferlin as well as synthesis and application thereof | 华东师范大学 | 2025-02-28 | — | — | CN | disclosed |
| CN-108473502-B | 4, 6-dihydropyrrolo [3,4-C ] pyrazole-5 (1H) -carbonitrile derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11306096-B2 | 4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-04-19 | — | — | US | disclosed |
| US-20210221813-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (AE) | 2021-07-22 | — | — | US | disclosed |
| EP-3430012-B1 | 4,6-DIHYDROPYRROLO[3,4-C]PYRAZOLE-5(1H)-CARBONITRILE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| CN-106543092-B | Bis- aromatic radical -1,2,4- triazole compound of 1,5- and its pharmaceutical applications | 华东师范大学 | 2019-05-17 | — | — | CN | disclosed |
| EP-3430012-A1 | 4,6 DIHYDROPYRROLO [3,4-C]PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017158381-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TRATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
| CN-106543092-A | 1,5 2 aromatic radical, 1,2,4 triazole compound and its pharmaceutical applications | 华东师范大学 | 2017-03-29 | — | — | CN | disclosed |
| CN-102977091-B | Fragrance alkyloyl tetrahydro-beta-carboline and the application of derivative in treatment metabolic disease thereof | EAST CHINA NORMAL UNIVERSITY (CN) | 2016-03-09 | — | — | CN | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
| WO-2002083652-A1 | DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
| US-6291470-B1 | DELTA-OPIOID ANTAGONIST HAVING HIGH SELECTIVITY AND ACTIVITY, THAT EXHIBITS IMMUNOSUPPRESSIVE ACTION, ANTIALLERGIC ACTION, ANTI-INFLAMMATORY ACTION AND BRAIN CELL-PROTECTING ACTION | TORAY INDUSTRIES, INC. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6087369-A | AN IMMUNOSUPPRESSIVE AGENT, ANTIALLERGIC AGENT, ANTI-INFLAMMATORY AGENT AND BRAIN CELL-PROTECTING AGENT | TORAY INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| CN-1043766-C | Indole derivative and preparation and pharmaceutical using of same | TORAY INDUSTRIES (JP) | 1999-06-23 | — | — | CN | disclosed |
| US-5852030-A | Indole derivatives, process for producing the same and medicinal uses of the same | TORAY INDUSTRIES, INC. (JP) | 1998-12-22 | — | — | US | disclosed |
| CN-1104412-A | Peripheral Vasodilating agent containing N-acylated 4-amino piperidine derivatives as active ingredients | OTSUKA PHARMA CO LTD (JP) | 1995-06-28 | — | — | CN | disclosed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
| CN-1092425-A | Indole derivatives, its manufacture method and medicinal use thereof | TORAY INDUSTRIES (JP) | 1994-09-21 | — | — | CN | disclosed |
| EP-0614898-A1 | INDOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221813-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | USP7, USP1, USP3 | ALDH1A1 567/4885RAB9A 1097/4885POLB 1842/4885 |
| US-11306096-B2 | 4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer | USP7, USP1, USP3 | ALDH1A1 567/4885RAB9A 1097/4885POLB 1842/4885 |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | ALDH1A1 316/4885RAB9A 1379/4885POLB 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.